Research Article| Volume 24, ISSUE 11, P982-985, November 2014

Screening for late-onset Pompe disease in Finland


      • We screened 108 myopathy patients for late-onset Pompe disease in Finland.
      • The screening did not reveal new Pompe patients.
      • Pompe disease is extremely rare in Finland.


      Pompe disease (glycogen storage disease type II) is caused by autosomal recessive mutations in GAA gene. The estimated frequency of late-onset Pompe disease is around 1:60,000. However, only two infantile and one late-onset Pompe patients have been reported in Finland with a population of 5 million. We screened for late-onset Pompe disease in a cohort of undetermined myopathy patients with proximal muscle weakness and/or elevated serum creatine kinase values. Acid α-glucosidase (GAA) activity in dried blood spots was measured and clinical data collected in 108 patients. Four patients had low normal GAA activity; all the others had activities well within the normal range. Re-analyses of these patients did not reveal new Pompe patients. Our findings suggest that Pompe disease is extremely rare in Finland. Finland is an example of an isolated population with enrichment of certain mutations for genetic disorders and low occurrence of some autosomal recessive diseases.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Neuromuscular Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kishnani P.S.
        • Steiner R.D.
        • Bali D.
        • et al.
        Pompe disease diagnosis and management guideline.
        Genet Med. 2006; 8: 267-288
      1. Leslie N, Tinkle BT. Glycogen storage disease type II (Pompe Disease) In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. GeneReviews™ [Internet]. Seattle (WA): Seattle, University of Washington; 1993–2013. 2007 Aug 31 [updated 2013 May 09].

        • Kishnani P.S.
        • Howell R.R.
        Pompe disease in infants and children.
        J Pediatr. 2004; 144: 35-43
        • Byrne B.J.
        • Kishnani P.S.
        • Case L.E.
        • et al.
        Pompe disease: design, methodology, and early findings from the Pompe Registry.
        Mol Genet Metab. 2011; 103: 1-11
        • Cupler E.J.
        • Berger K.I.
        • Leshner R.T.
        • et al.
        AANEM consensus committee on late-onset Pompe disease: AANEM consensus committee on late-onset Pompe disease. consensus treatment recommendations for late-onset Pompe disease.
        Muscle Nerve. 2012; 45: 319-333
        • Zhang H.
        • Kallwass H.
        • Young S.P.
        • et al.
        Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease.
        Genet Med. 2006; 8: 302-306
        • Mechtler T.P.
        • Metz T.F.
        • Müller H.G.
        • et al.
        Short-incubation mass spectrometry assay for lysosomal storage disorders in newborn and high-risk population screening.
        J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 908: 9-17
        • Ausems M.G.
        • Verbiest J.
        • Hermans M.P.
        • et al.
        Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counseling.
        Eur J Hum Genet. 1999; 7: 713-716
        • Martiniuk F.
        • Chen A.
        • Mack A.
        • et al.
        Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease.
        Am J Med Genet. 1998; 79: 69-72
        • Vanto T.
        • Salmi T.T.
        • Kalimo H.
        • et al.
        Pompe’s disease or glycogen storage disease.
        Duodecim. 1982; 98 ([Finnish]): 709-716
        • Korpela M.P.
        • Paetau A.
        • Löfberg M.I.
        • Timonen M.H.
        • Lamminen A.E.
        • Kiuru-Enari S.M.
        A novel mutation of the GAA gene in a Finnish late-onset Pompe disease patient: clinical phenotype and follow-up with enzyme replacement therapy.
        Muscle Nerve. 2009; 40: 143-148
        • Chamoles N.A.
        • Niizawa G.
        • Blanco M.
        • Gaggioli D.
        • Casentini C.
        Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper.
        Clin Chim Acta. 2004; 347: 97-102
        • Winchester B.
        • Bali D.
        • Bodamer O.A.
        • et al.
        Pompe disease diagnostic working group methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting.
        Mol Genet Metab. 2008; 93: 275-281
      2. Bodamer OA, Dajnoki A. Diagnosing lysosomal storage disorders: Pompe disease. Curr Protoc Hum Genet 2012 Oct; Chapter 17, Unit 17.

        • Preisler N.
        • Lukacs Z.
        • Vinge L.
        • et al.
        Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies.
        Mol Genet Metab. 2013; 110: 287-289
        • Kroos M.A.
        • Van der Kraan M.
        • Van Diggelen O.P.
        • et al.
        Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients.
        J Med Genet. 1995; 32: 836-837
        • de la Chapelle A.
        Disease gene mapping in isolated human populations: the example of Finland.
        J Med Genet. 1993; 30: 857-865
        • Norio R.
        • Nevanlinna H.R.
        • Perheentupa J.
        Hereditary diseases in Finland; rare flora in rare soil.
        Ann Clin Res. 1973; 5: 109-141